Overview

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors

Status:
Completed
Trial end date:
2018-03-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test mirvetuximab soravtansine (IMGN853) in participants with ovarian cancer and other FOLR-1 positive tumors.
Phase:
Phase 1
Details
Lead Sponsor:
ImmunoGen, Inc.
Treatments:
Maytansine